生物途径的抑制剂的遗传选择
T C Norman1, D L Smith, P K Sorger
1Department of Physiology, University of California, San Francisco, CA 94143-0444, USA. tnorman@microbia.com
Science (New York, N.Y.)
|July 27, 1999
概括
研究人员开发了载体蛋白内的体或体,以抑制酵母生物通路. 这些聚体专门针对关键的细胞过程,为药物发现和研究复杂的遗传系统提供了潜力.
科学领域:
- 分子生物学分子生物学
- 酵母遗传学 酵母遗传学
- 系统生物学 系统生物学
背景情况:
- 开发抑制特定生物通路的工具对于理解细胞功能至关重要.
- 可以被设计为细胞内抑制剂,但它们的传递和稳定性仍然是挑战.
研究的目的:
- 开发和利用peptamers作为细胞内抑制剂来探测芽发酵酵母中的生物途径.
- 为了确定这些胺基的分子标,并评估它们的特异性.
主要方法:
- 基因选择被用来分离针对特定酵母途径的培体.
- 佩普塔默被用催化不活的葡萄球菌核酶衍生物作为载体蛋白进行细胞内表达.
- 两种混合分析和遗传剖析被用来识别peptamer目标;转录数组评估了特异性.
主要成果:
- 成功地分离了抑制激素信号传递,转录沉默和螺杆检查点的胺.
- 鉴定出Ydr517w是螺旋检查点组件,证实了Ste50在激素信号传递中的双重作用.
- 转录阵列分析揭示了聚对细胞通路的影响的高特异性.
结论:
- 工程化胺是有效的细胞内抑制剂,用于剖析芽发酵酵母中的生物通路.
- 这些胺体具有很高的特异性,使它们成为遗传研究和药物标识的宝贵工具.
- 该方法适用于缺乏先进遗传工具的生物和发现新药点.
相关概念视频
00:57Antibiotic Selection
Overview
01:16In-vitro Mutagenesis
To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
01:38Limits to Natural Selection
Organisms that are well-adapted to their environment are more likely to survive and reproduce. However, natural selection does not lead to perfectly adapted organisms. Several factors constrain natural selection.For one, natural selection can only act upon existing genetic variation. Hypothetically, redtusks may enhance elephant survival by deterring ivory-seeking poachers. However, if there are no gene variants—or alleles—for redtusks, natural selection cannot increase the prevalence of...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...